Complexes of Amyloid-β and cystatin C in the human central nervous system

Weiqian Mi, Sonia S. Jung, Haung Yu, Stephen D. Schmidt, Ralph A. Nixon, Paul M. Mathews, Fabrizio Tagliavini, Efrat Levy

Research output: Contribution to journalArticle

Abstract

A role for cystatin C (CysC) in the pathogenesis of Alzheimer's disease (AD) has been suggested by the genetic linkage of a CysC gene (CST3) polymorphism with late-onset AD, the co-localization of CysC with amyloid-β (Aβ) in AD brains, and binding of CysC to soluble Aβ in vitro and in mouse models of AD. This study investigates the binding between Aβ and CysC in the human central nervous system. While CysC binding to soluble Aβ was observed in AD patients and controls, a SDS-resistant CysC/Aβ complex was detected exclusively in brains of neuropathologically normal controls, but not in AD cases. The association of CysC with Aβ in brain from control individuals and in cerebrospinal fluid reveals an interaction of these two polypeptides in their soluble form. The association between Aβ and CysC prevented Aβ accumulation and fibrillogenesis in experimental systems, arguing that CysC plays a protective role in the pathogenesis of AD in humans and explains why decreases in CysC concentration caused by the CST3 polymorphism or by specific presenilin 2 mutations can lead to the development of the disease. Thus, enhancing CysC expression or modulating CysC binding to Aβ have important disease-modifying effects, suggesting a novel therapeutic intervention for AD.

Original languageEnglish
Pages (from-to)273-280
Number of pages8
JournalJournal of Alzheimer's Disease
Volume18
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Cystatin C
Amyloid
Central Nervous System
Alzheimer Disease
Brain
Presenilin-2
Genetic Linkage
Cerebrospinal Fluid

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Amyloid-β protein precursor
  • Cystatin C

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Mi, W., Jung, S. S., Yu, H., Schmidt, S. D., Nixon, R. A., Mathews, P. M., ... Levy, E. (2009). Complexes of Amyloid-β and cystatin C in the human central nervous system. Journal of Alzheimer's Disease, 18(2), 273-280. https://doi.org/10.3233/JAD-2009-1147

Complexes of Amyloid-β and cystatin C in the human central nervous system. / Mi, Weiqian; Jung, Sonia S.; Yu, Haung; Schmidt, Stephen D.; Nixon, Ralph A.; Mathews, Paul M.; Tagliavini, Fabrizio; Levy, Efrat.

In: Journal of Alzheimer's Disease, Vol. 18, No. 2, 2009, p. 273-280.

Research output: Contribution to journalArticle

Mi, W, Jung, SS, Yu, H, Schmidt, SD, Nixon, RA, Mathews, PM, Tagliavini, F & Levy, E 2009, 'Complexes of Amyloid-β and cystatin C in the human central nervous system', Journal of Alzheimer's Disease, vol. 18, no. 2, pp. 273-280. https://doi.org/10.3233/JAD-2009-1147
Mi, Weiqian ; Jung, Sonia S. ; Yu, Haung ; Schmidt, Stephen D. ; Nixon, Ralph A. ; Mathews, Paul M. ; Tagliavini, Fabrizio ; Levy, Efrat. / Complexes of Amyloid-β and cystatin C in the human central nervous system. In: Journal of Alzheimer's Disease. 2009 ; Vol. 18, No. 2. pp. 273-280.
@article{fc1bfb3218714ed79543d9162c4950de,
title = "Complexes of Amyloid-β and cystatin C in the human central nervous system",
abstract = "A role for cystatin C (CysC) in the pathogenesis of Alzheimer's disease (AD) has been suggested by the genetic linkage of a CysC gene (CST3) polymorphism with late-onset AD, the co-localization of CysC with amyloid-β (Aβ) in AD brains, and binding of CysC to soluble Aβ in vitro and in mouse models of AD. This study investigates the binding between Aβ and CysC in the human central nervous system. While CysC binding to soluble Aβ was observed in AD patients and controls, a SDS-resistant CysC/Aβ complex was detected exclusively in brains of neuropathologically normal controls, but not in AD cases. The association of CysC with Aβ in brain from control individuals and in cerebrospinal fluid reveals an interaction of these two polypeptides in their soluble form. The association between Aβ and CysC prevented Aβ accumulation and fibrillogenesis in experimental systems, arguing that CysC plays a protective role in the pathogenesis of AD in humans and explains why decreases in CysC concentration caused by the CST3 polymorphism or by specific presenilin 2 mutations can lead to the development of the disease. Thus, enhancing CysC expression or modulating CysC binding to Aβ have important disease-modifying effects, suggesting a novel therapeutic intervention for AD.",
keywords = "Alzheimer's disease, Amyloid-β, Amyloid-β protein precursor, Cystatin C",
author = "Weiqian Mi and Jung, {Sonia S.} and Haung Yu and Schmidt, {Stephen D.} and Nixon, {Ralph A.} and Mathews, {Paul M.} and Fabrizio Tagliavini and Efrat Levy",
year = "2009",
doi = "10.3233/JAD-2009-1147",
language = "English",
volume = "18",
pages = "273--280",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Complexes of Amyloid-β and cystatin C in the human central nervous system

AU - Mi, Weiqian

AU - Jung, Sonia S.

AU - Yu, Haung

AU - Schmidt, Stephen D.

AU - Nixon, Ralph A.

AU - Mathews, Paul M.

AU - Tagliavini, Fabrizio

AU - Levy, Efrat

PY - 2009

Y1 - 2009

N2 - A role for cystatin C (CysC) in the pathogenesis of Alzheimer's disease (AD) has been suggested by the genetic linkage of a CysC gene (CST3) polymorphism with late-onset AD, the co-localization of CysC with amyloid-β (Aβ) in AD brains, and binding of CysC to soluble Aβ in vitro and in mouse models of AD. This study investigates the binding between Aβ and CysC in the human central nervous system. While CysC binding to soluble Aβ was observed in AD patients and controls, a SDS-resistant CysC/Aβ complex was detected exclusively in brains of neuropathologically normal controls, but not in AD cases. The association of CysC with Aβ in brain from control individuals and in cerebrospinal fluid reveals an interaction of these two polypeptides in their soluble form. The association between Aβ and CysC prevented Aβ accumulation and fibrillogenesis in experimental systems, arguing that CysC plays a protective role in the pathogenesis of AD in humans and explains why decreases in CysC concentration caused by the CST3 polymorphism or by specific presenilin 2 mutations can lead to the development of the disease. Thus, enhancing CysC expression or modulating CysC binding to Aβ have important disease-modifying effects, suggesting a novel therapeutic intervention for AD.

AB - A role for cystatin C (CysC) in the pathogenesis of Alzheimer's disease (AD) has been suggested by the genetic linkage of a CysC gene (CST3) polymorphism with late-onset AD, the co-localization of CysC with amyloid-β (Aβ) in AD brains, and binding of CysC to soluble Aβ in vitro and in mouse models of AD. This study investigates the binding between Aβ and CysC in the human central nervous system. While CysC binding to soluble Aβ was observed in AD patients and controls, a SDS-resistant CysC/Aβ complex was detected exclusively in brains of neuropathologically normal controls, but not in AD cases. The association of CysC with Aβ in brain from control individuals and in cerebrospinal fluid reveals an interaction of these two polypeptides in their soluble form. The association between Aβ and CysC prevented Aβ accumulation and fibrillogenesis in experimental systems, arguing that CysC plays a protective role in the pathogenesis of AD in humans and explains why decreases in CysC concentration caused by the CST3 polymorphism or by specific presenilin 2 mutations can lead to the development of the disease. Thus, enhancing CysC expression or modulating CysC binding to Aβ have important disease-modifying effects, suggesting a novel therapeutic intervention for AD.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Amyloid-β protein precursor

KW - Cystatin C

UR - http://www.scopus.com/inward/record.url?scp=70350508170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350508170&partnerID=8YFLogxK

U2 - 10.3233/JAD-2009-1147

DO - 10.3233/JAD-2009-1147

M3 - Article

C2 - 19584436

AN - SCOPUS:70350508170

VL - 18

SP - 273

EP - 280

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -